Login to Your Account



Heading Toward Profitability, Vertex Files NDA for CF Drug

By Jennifer Boggs


Thursday, October 20, 2011
Even as analysts are looking for Vertex Pharmaceuticals Inc. to report a third-quarter profit next week on better-than-expected sales of hepatitis C drug Incivek (telaprevir), the Cambridge, Mass.-based biotech is gearing up to launch a second drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription